Mukka Proteins Completes Acquisition of Ocean Proteins, Making it a Subsidiary
Mukka Proteins Limited acquired 1,04,500 equity shares of Ocean Proteins Private Limited for ₹1.045 crore. This acquisition makes Ocean Proteins a subsidiary, with Mukka Proteins now holding 51% stake. The move is part of Mukka's strategy to expand its Frozen Fish business.
The acquisition of a subsidiary is a significant corporate action that can impact the company's future growth and financial performance, warranting a medium impact assessment.
The acquisition of Ocean Proteins Private Limited and its subsequent becoming a subsidiary is a strategic move for Mukka Proteins to expand its business, which is viewed positively.
Mukka Proteins Limited has announced the completion of its further acquisition of 1,04,500 equity shares in Ocean Proteins Private Limited (OPPL) for a total consideration of ₹1.045 crore (Rupees One Crore Four Lakh and Fifty Thousand Only). The acquisition, which involved shares with a face value of ₹100 each at face value, was completed on December 30, 2025.
As a result of this acquisition, Ocean Proteins Private Limited has now become a subsidiary of Mukka Proteins Limited, with Mukka Proteins holding a 51% shareholding post-acquisition. OPPL is engaged in the manufacturing and export of Frozen Fish, Shrimp, and Surmi. Its authorized capital is ₹10 crore and paid-up capital is ₹9.50 crore. For the financial year 2024-25, OPPL reported a turnover of ₹50.70 crore and a Profit After Tax (PAT) of (₹0.8156 crore).
This strategic investment is part of Mukka Proteins' plans to expand its Frozen Fish business. OPPL was previously an associate company and a related party. The investment was made on an arm's length basis, with promoters having an interest through their directorship.
What to do with a filing like this
Mukka Proteins Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mukka Proteins Limited. Read the original for the full detail.